Reports of ABA-1L versus adalimumab-1L in bDMARD-naïve RA patients indicated that ABA-1L was cost-effective, especially in anti-citrullinated protein antibody (ACPA)-positive patients [6, 21]. Here, PRTN3 is linked to rheumatoid arthritis.